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PEDIATRIC LIVER TRANSPLANTATION: PROSPECTS FOR LINEAR GROWTH 
Andrew H. Urbach, H.D., J. Carlton Cartner, Jr., H.D., J. Jeffrey 
Malatack, H.D., Basil J. ZitelU, H.D., and Thomas E. Starzl, H.D. 
The Unt attempt at liver transplantation in humans 10111 lIIade 
in 1963 (1). The first loog term survivor was transplanted on July 
23, 1967. She was a one-and-one-half-year-old girl who lived for 13 
!Donths before she .uccumbed to the hepatocellular carcinoma for 
which she was treated. During the year. 1963-1979, Dr. Thoma. 
Starzl performed liver tran8plantation on 170 patient. including 86 
children (2). Survival at five years was Ie •• than 30% with younger 
patient8, .howing a 10% survival advantage over adult.. Not until 
the discovery of cyclosporine (3, 4) and the initiation of clinical 
trials did survival increase significantly. As a direct result of 
this 8uccess, the number of patients who underwent the procedure 
climbed and an innovative and aggressive procedure became accepted 
therapy for end-stage liver disease (5); however, a multitude of 
questions remain about the quality of life of these patients. The 
purpose of this review is to addres8 one aspect of this issue, 
linear growth • 
OVERALL SURVIVAL 
FrOID Hay 1981 to Hay 1986, 229 children received 303 liver 
transplants at the Children'. Hospital of Pittsburgh. Overall 
survival rate as of Kay 1986 wa's 71%. Table 1 shows overall 
survival rate8 for each year while Table 2 reviews survival rates of 
children undergoing retransplantatioo compared with those of 
children receiving only one transplant. 
GROWTH 
From Hay 1981 to June 1983, 49 children received liver 
transplants and 29 survivors were evaluated for growth potential 
(6). Their average age at the time of transplant was flve-and-one-
half years (7 IDO. - 13 years) and sll were Tanner Stage 1. 
Transplantation was performed for a wide variety of liver diseases. 
Nearly half of the patients had biliary atresia. Metabolic 
disorders such as alphal antitrypsin deficiency and tyrosinemia 
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accounted for the next largest group. I mmunosupprenlon " •• 
accomplished with an average dose of 9.4 ag/kg/day of cyclosporlne 
and 0.21 mg/kg/ day of prednisone (6, 7). Twenty-U ve of 29 patient. 
were on less than 5 mg of prednisone per day. Average length of 
follow-up was three years (24 - 52 months). 
TABLE 1 
Yearly survival rates at the Children's Hospitsl of Pittsburgh fro. 
Hay 1981-Hay 1986. 
OVERALL 
NUHBER NUMBER SURVIVAL 
OF OF FOR 
~ TRANSPLANTS CHILDREN DEATHS COHORT 
5/81-6/82 30 25 9 64% 
7/82-6/83 38 25 10 60% 
7/83-6/84 63 50 8 84% 
7/84-6/85 79 57 14 75% 
7/85-5/86 93 72 25 65% 
Overall 303 229 66 71% 
TABLE 2 
Survival rates bases on need for retransp1antation at the Children's 
Hospital of Pittsburgh from Hay 1981-1986 
t.1JHBER 
or 
9HILDREN 
166 
51 
11 
NUMBER 
OF 
TRANSPLANn 
2 
3 
4 
DEATHS 
38 
24 
4 
o 
OVERALL 
SURVIVAL 
77% 
53% 
64% 
100% 
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Twenty-eight percent (8/29) croased percentiles in an upward 
direction (had greater than normal growth velocity for age) and were 
also above the fifth percentile on a .tandard growth curve at the 
end of the study. Fourteen percent (4/29) were above the fifth 
percentile prior to transplantation and maintained a normal growth 
pattern with no change in percentile. Forty-five percent (13/29) 
were below the fifth percentile prior to surgery and remained less 
than the fifth percentile following surgery. Within this group, 
however, 10 of 13 (77%) attained normal or accelerated growth 
velocity. Fourteen percent (4/29) began above the fifth percentile 
and fell to below this level at the time of their last evaluation. 
Of the seven patients with poor growth, the majority suffered from 
chronic rejection or a recurrence of the disease for which the 
transplant was performed (8). Overall, 76% of our patients achieved 
normal or accelerated growth velocity. 
DISCUSSION 
A great deal of the concern a')out growth in renal transplant 
recipients has centered around tie effects of steroids on the 
developing child. Many mechanisms for steroid-induced growth 
failure have been suggested. These include abnormalities of calcium 
and phosphorus metabolism, a direct effect on cell metabolism, and 
inhibitory effects on growth hormone and somatomedin activity (9, 
10, 11). Speci fically, linear growth seems to be related to 
prednisone dosages and scheduling intervals. Lilly (12) and DeShazo 
(13) showed that with prednisone dosages between 0.2 and 0.3 
mg/kg/day, good growth could occur. Better growth is felt to occur 
when alternate day therapy is utilized (14, 15), particularly in 
patients with a bone age of less than 12 years (16, 17, 18). 
Concerns, however, have been raised about the immunosuppressive 
efficacy of an every-other-day steroid regimen (14, 15, 19,20) and 
many authors reserve this therapy for a child with poor growth whose 
graft function is excellent on daily prednisone. Data on graft 
survival with administration of every-other-day prednisone Is not 
available for liver transplantatio~ 
Detailed growth studies with the use of cyclosporine and 
prednisone for immunosuppression are limited to renal transplant 
patients. Conley (21) and Klare (22) report optimism, but of the 10 
patients discussed, the latter report (22), four children received 
no prednisone at all. The other six children received low dose 
prednisone, 8.5 mg/1.73m 2/day. Ellis (23), on the other hand, 
reports more disappointing results with growth, using the same 
fm~unosuppressive drugs. Utilizing a mean dose of 0.25 mg/kg/day of 
prednisone, growth .... as suboptimal or poor In seven of eIght 
patients. 
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Linear growth failure ia a prominent feature of end-atage liver 
disease (24). In the pre-cyclosporine era, some authorl (2S) 
expresaed reluctance to perform transplant. in pediatric patient •• 
Much of their hesitancy revolved around the growth retardation and 
the lIultitude of aide effects of high dose corticosteroid.. With 
the advent of cyclosporine as a potent immunosuppressive agent (3, 
4), the nece881ty to utilize high dose prednisone in liver 
transplant patients lessened. Until recently no data were available 
on growth following Uver transplantation 1n the cyclosporine era. 
Two articles (26, 27) briefly referred to the observation that good 
growth could be achieved; however, these impressions were limited in 
scope because of the short length of follow-u~ 
Our report (6) indicates that good growth in pediatric liver 
transplant recipients is possible using cyclosporine with a daily 
prednisone dose of 0.21 mg/kg/day. We also show that most growth 
failure was predictable on the basis of poor graft function. The 
improvement in linear growth is likely to be multifactorial. 
Factors which account for good growth include disappearance of 
metabolic bone disease, good nutrition, improved hepatic function 
and the general state of well being that these patients achieve 
(27). By allowing lower doses of prednisone to be utilized, the 
effectiveness of cyclospor1ne has also contributed to the positive 
results that we have presented. We further believe that the risks 
of alternate day steroids on graft survival may not currently 
warrant every-other-day dosing considering the growth data presented 
here. These data provide support for our current immunosuppression 
regimen of cyclosporine and low dose prednisone. Future 
investigation should emphasize therapeutic methods which enhance 
growth while preventing chronic rejection. 
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